Cantor Fitzgerald Downgrades Cognition Therapeutics (CGTX) to Neutral
Tweet
Share
E-mailGet Alerts CGTX Hot Sheet
Price: $1.01 -2.88%
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
6 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Cantor Fitzgerald analyst Charles Duncan downgraded Cognition Therapeutics (NASDAQ: CGTX) from Overweight to Neutral.
For an analyst ratings summary and ratings history on Cognition Therapeutics click here. For more ratings news on Cognition Therapeutics click here.
Shares of Cognition Therapeutics closed at $2.37 yesterday.
You May Also Be Interested In
- H.C. Wainwright Reiterates Buy Rating on Cognition Therapeutics (CGTX)
- Barclays Downgrades Murphy Oil Corp. (MUR) to Underweight
- Goldman Sachs Downgrades Douglas AG (DOU:GR) to Sell
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
